RFA-GH-21-006, Establishing the Southeast Asia Serological Surveillance Network (SASSNet) for Emergent, Endemic, and Vaccine-Preventable Infections

项目摘要 该项目旨在建立东南亚血清学监测网络 (SASSNet)以及在印度尼西亚和越南的业务。网络将应用优化的和 新出现和暴露的有效血清学采样、分析和报告 地方性被忽视的具有区域重要性的热带传染病。该项目 利用机器人ELISA和Luminex多路高通量平台 有效和可持续地监测数十种感染/疫苗接种。抽样策略是 年龄分层匿名残血标本的实用化方法 印度尼西亚的25家医院和越南的20家医院的网络。该项目加入了学术界 来自牛津大学印尼临床研究部门的研究伙伴和 越南与两国卫生部内的研究人员进行了合作。第一 一年的工作主要集中在SARS-CoV-2至3的血清学监测上 明确的工作流程：1)建立常规的国家血清学监测方法；2) 选定地点暴露于SARS-CoV的横断面调查；以及3)以下两项 通过酶联免疫吸附试验进行1年的血清学评估的纵向队列，其中 在SARS-CoV-2 qPCR阳性之后，立即在一个队列中登记，在 其他人则立即接种新冠肺炎疫苗。第一年也将看到优化 和验证对6个不同的SARS-CoV-2抗原靶标和 三种不同的免疫球蛋白(A、M和G)以及S蛋白S1和N蛋白 MERS冠状病毒和四种季节性冠状病毒。同样的多重检测稍后将包括 八种新出现的感染(例如尼帕病毒、寨卡病毒和日本脑炎病毒)，被忽视 热带感染(如登革热、疟疾、丝虫病、麻风病和肠道蠕虫硫酶)， 和疫苗可预防的感染(如麻疹、白喉和破伤风)。那个多厅影院 血清学检测将构成常规国家血清学监测的基础，以及 该项目的目的是在印度尼西亚卫生部设施内建设这一能力，并 越南，并在5个月结束时将这些设施移交给各自的当局-- 项目生命周期的年份。

Project Summary The project aims to establish the Southeast Asian Serological Surveillance Network (SASSNet) and operations in Indonesia and Viet Nam. The Network will apply optimized and validated serological sampling, analysis, and reporting of exposures to emerging and endemic neglected tropical infectious diseases of regional importance. The project leverages both robotic ELISA and Luminex multiplex high throughput platforms in order to efficiently and sustainably surveil several dozen infections/vaccinations. Sampling strategy is the pragmatic approach of age-stratified anonymized residual blood specimens from networks of 25 hospitals in Indonesia and 20 in Viet Nam. The project joins academic research partners from the University of Oxford’s clinical research units in Indonesia and Viet Nam with researchers within the respective Ministry of Health in both nations. The first year of effort focuses exclusively on serological surveillance of SARS-CoV-2 through 3 distinct workstreams: 1) establishing routine national serological surveillance by ELISA; 2) cross-sectional surveys for exposure to SARS-CoV at selected sites; and 3) following two longitudinal cohorts for serological assessment by ELISA over a 1-year period, where enrollment in one cohort immediately follows qPCR positivity for SARS-CoV-2, and in the other immediately follows vaccination against COVID-19. Year 1 will also see the optimizing and validation of a multiplex Luminex assay for six distinct SARS-CoV-2 antigenic targets and three distinct immunoglobulins (A, M, and G), along with Spike S1 and Spike N proteins of MERS-CoV, and four seasonal coronaviruses. The same multiplex assay will later include eight emerging infections (e.g. Nipah, Zika, and Japanese encephalitis viruses), neglected tropical infections (e.g., Dengue, malaria, filariasis, leprosy, and intestinal helminthiases), and vaccine-preventable infections (e.g. measles, diphtheria, and tetanus). That multiplex serological assay will constitute the basis of routine national serological surveillance, and the project aims to build that capacity within Ministry of Health facilities in Indonesia and Viet Nam, and to turn those facilities over to the respective authorities at the end of the 5- year life of the project.